Nuvectis Pharma, Inc.
NVCT- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001875558
No open-market purchases or sales by Nuvectis Pharma, Inc. insiders were filed in the last 90 days; 94 institutions reported holding it in 13F filings for Q3 2026, worth $272.1M in total; no superinvestor holds it.
Key figures
- Market capClose on Nov 18, 2026
- $697.8M
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ3 2026, +13 vs. previous quarter
- 94
- 13F valueReported value at the end of Q3 2026
- $272.1M
- Superinvestors holdingAt the end of Q3 2026
- 0
Price chart
Financials
See financial statementsFrom SEC filings, in USD.
- Revenue, FY2025
- –
- No comparable prior period
- Net income, FY2025
- -$26.4M
- No comparable prior period
- Free cash flow, FY2025
- –
- No comparable prior period
- Revenue, Q3 FY2026
- –
- No comparable prior period
Short interest
See short dataFrom FINRA, settlement date Oct 30, 2026.
- Short interest
- 2.54M
- Shares sold short
- Change
- +144.1K
- +6.0% vs. previous
- Days to cover
- 15.16
- At average daily volume
Superinvestors holding NVCT, Q3 2026
Go to the superinvestors tabNo superinvestor reported holding NVCT at the end of Q3 2026.
Latest insider trades
See all insider tradesOpen-market purchases and sales by Nuvectis Pharma, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jul 1, 2026 (view filing)1:41 PM ET | Jun 30 | 1 day | Mosseri Marlio Charles10% Owner | PPurchase | +50.0K | $18.32 | +$916.0K | +1.6%3.19M after | |
| Jul 1, 2026 (view filing)1:39 PM ET | Jun 30 | 1 day | Bentsur RonChairman & CEO | PPurchase | +12.5K | $20.00 | +$250.0K | +0.3%3.69M after | |
| Nov 6, 2025 (view filing) | Nov 5 | 1 day | Bentsur RonChairman & CEO | PPurchase | +5.00K | $5.72 | +$28.6K | +0.1%3.53M after | |
| Nov 6, 2025 (view filing) | Nov 5 | 1 day | Sanchez JuanDirector | PPurchase | +13.0K | $5.79 | +$75.3K | +20.0%78.2K after | |
| Nov 6, 2025 (view filing) | Nov 5 | 1 day | Kaplan Matthew L.Director | PPurchase | +11.0K | $5.84 | +$64.2K | +9.7%124.8K after | |
| Oct 29, 2025 (view filing) | Oct 23-27 | 6 daysLate | Mosseri Marlio Charles10% Owner | PPurchase | +154.8K | $6.18 | +$957.1K | +5.2%3.14M after | 3 lots |
| Jun 24, 2025 (view filing) | Jun 20 | 4 days | Mosseri Marlio Charles10% Owner | PPurchase | +5.60K | $7.99 | +$44.8K | +0.2%2.98M after | |
| Jun 20, 2025 (view filing) | Jun 17-18 | 3 days | Mosseri Marlio Charles10% Owner | PPurchase | +33.4K | $8.06 | +$269.5K | +1.1%2.98M after | 2 lots |
| May 13, 2025 (view filing) | May 12 | 1 day | Mosseri Marlio Charles10% Owner | PPurchase | +21.2K | $8.11 | +$171.7K | +0.7%2.94M after | |
| May 12, 2025 (view filing) | May 8-9 | 4 days | Mosseri Marlio Charles10% Owner | PPurchase | +27.7K | $8.94 | +$247.3K | +1.0%2.94M after | Amended6 lots |
Top 10 13F holders, Q3 2026
See all 94 holdersThe largest institutional positions in Nuvectis Pharma, Inc. at the end of Q3 2026; share changes are against Q2 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Soleus Capital Management, L.P. | 1,710,658 | $36.1M | 1.28% | +710,658+71.1% | Added |
| Tang Capital Management LLC | 1,577,968 | $33.3M | 1.53% | +27,968+1.8% | Added |
| Braidwell LP | 1,573,823 | $33.2M | 1.38% | +1,573,823 | New |
| BlackRock, Inc. | 1,306,975 | $27.6M | 0.00% | +305,690+30.5% | Added |
| Vanguard Capital Management LLC | 907,271 | $19.2M | 0.00% | +34,789+4.0% | Added |
| Iridian Asset Management LLC | 793,207 | $16.8M | 6.09% | +16,129+2.1% | Added |
| Geode Capital Management, LLC | 503,368 | $10.6M | 0.00% | +71,095+16.4% | Added |
| Parkman Healthcare Partners LLC | 425,351 | $8.98M | 0.81% | +425,351 | New |
| Baldwin Brothers Inc | 382,015 | $8.07M | 0.53% | 00.0% | Unchanged |
| State Street Corp | 368,995 | $7.79M | 0.00% | +120,797+48.7% | Added |
Holders of 5% or more of NVCT
See all 1 holders and filingsHolders whose latest Schedule 13D or 13G filing reports 5% or more of Nuvectis Pharma, Inc..
| Holder | Latest form | Stake | Change | First filed | Latest filing | Filing |
|---|---|---|---|---|---|---|
| Soleus Private Equity Fund III, L.P. | 13G | 5.10%1.65M shares | New | Aug 6, 20261 filing | Aug 6, 2026 | SEC |